← Back

Wire · opportunities

FDA Approval of Daraxonrasib in Pancreatic Cancer

Published

11 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

The FDA approved daraxonrasib, the first pan-RAS targeted therapy for metastatic pancreatic cancer, demonstrating improved overall survival, progression-free survival, and quality of life compared to chemotherapy. This approval marks a paradigm shift in treatment strategies and opens new clinical trial pathways.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

Your pancreatic cancer treatment biotech just gained a new competitor redefining survival benchmarks. Daraxonrasib's approval expands who you must outperform and sets a new standard for clinical trial design.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-cancertargeted-therapyclinical-trialsbiotech-drug